A change in the availability of treatments for BRAF-mutated CRC over the past decade, particularly the introduction of dual BRAF and EGFR inhibition for V600BRAF-mutated CRC and checkpoint inhibition for dMMR CRC into standard of care practice, limits the interpretation of the older cohort. This evidence concerns the gene BRAF and colorectal carcinoma.